Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AVXL SUED FOR SECURITIES LAW VIOLATIONS!!!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93774016/anavex-life-sciences-corporation-sued-for-securiti
NEW YORK, May 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
The Gross Law Firm (PRNewsfoto/The Gross Law Firm)
Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=77824&from=4
CLASS PERIOD: February 1, 2022 to January 1, 2024
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
DEADLINE: May 13, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=77824&from=4
JOIN THE CLASS ACTION SUIT AGAINST AVXL!!!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93721517/may-13-2024-deadline-contact-the-gross-law-firm#
NEW YORK, April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
The Gross Law Firm (PRNewsfoto/The Gross Law Firm)
Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=76939&from=4
CLASS PERIOD: February 1, 2022 to January 1, 2024
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
SOME INSTITUTION HAS SOLD OVER 242,00 SHARES OF AVXL THUS FAR TODAY, 23 APRIL 2024!!!!!
SOME INSTITUTION SOLD 279,187 SHARES OF AVXL AT 5:16:40 YESTERDAY DURING THE AFTER HOUR TRADING FOR $3.68 PER SHARE!!!!!!
https://www.nasdaq.com/market-activity/stocks/avxl/after-hours-trades
GOOD LUCK AND GOD BLESS!!!!!!!
EXPECT AVXL TO CLOSE AT $1249 NEXT WEEK!!!!!!
EMA?, WHAT HAPPENED TO THE A-73 TGA APPROVAL THE WGT CREW CLAIMED HAS BEEN IMMINENT SINCE 2017?
CLASS ACTION LAWSUIT FILED AGAINST AVXL!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93642232/class-action-filed-against-anavex-life-sciences-co
Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=75202&from=4
CLASS PERIOD: February 1, 2022 to January 1, 2024
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
INVESTORS WHO LOST MONEY ON AVXL- CLASS ACTION LAWSUIT!!!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93662788/the-gross-law-firm-reminds-shareholders-of-a-lead
NEW YORK, April 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
The Gross Law Firm (PRNewsfoto/The Gross Law Firm)
Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=75587&from=4
CLASS PERIOD: February 1, 2022 to January 1, 2024
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
YOU HAVE BEEN POSTING A2-73 TGA PROVISIONAL APPROVAL IS IMMINENT SINCE 2018!!!!!!
STFU!!!!!!
You have been posting B.S. since 2018...
STFU
YOU HAVE BEEN MAKING THE SAME CLAIM ABOUT A2-73 TGA APPROVAL SINCE 2018!!!!!!! 😹😹😹
Blarcamesine will reduce healthcare costs, I expect the EU to approve it soon.
HUUUUUUUGE ----- DOT -------!!!!!!! 🤣🤣🤣
Posted by "Michael" on Anavex's Investor Forum-Facebook---good stuff !!!
THE WGT CREW CLAIMED THE SAME ABOUT A2-73 PROVISIONAL APPROVAL BY THE TGA IN 2018 ?????
mrp--"As evidenced by Exactly what?" have you not been following the most recent guidelines set by the FDA re: AD and Precision Medicine ????? Anavex's forte ????
THE WGT CREW CLAIMED THE SAME ABOUT A2-73 PROVISIONAL APPROVAL BY THE TGA IN 2018 ?????
FDA has now bought into the Anavex theory.
INVESTORS WHO LOST MONEY ON AVXL- CLASS ACTION LAWSUIT!!!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93548303/investors-who-lost-money-on-anavex-life-sciences-c
NEW YORK, March 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
The Gross Law Firm (PRNewsfoto/The Gross Law Firm)
Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=72579&from=4
CLASS PERIOD: February 1, 2022 to January 1, 2024
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
JOIN THE CLASS ACTION LAWSUIT AGAINST AVXL!!!!!!
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/93575330/lost-money-on-anavex-life-sciences-corporationavxl
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct 'complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
DEADLINE: May 13, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/anavex-life-sciences-loss-submission-form/?id=73179&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AVXL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 13, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
ANAVEX LIFE SCIENCES CORPORATION CLASS ACTION LAWSUIT- AVXL
https://www.rgrdlaw.com/cases-anavex-life-sciences-corporation-class-action-lawsuit-avxl.html
The Anavex class action lawsuit seeks to represent purchasers or acquirers of Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”). Captioned Blum v. Anavex Life Sciences Corporation, No. 1:24-cv-01910 (S.D.N.Y.), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Anavex class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
CASE ALLEGATIONS: Anavex investigates, manufactures, and markets pharmaceuticals for central nervous system (“CNS”) disorders. According to the complaint, Anavex’s primary product is blarcamesine and Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
The Anavex class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants misled investors by providing a materially flawed and inaccurate impression of Anavex’s research program and of blarcamesine’s actual likelihood of success in the Rett syndrome trials.
The Anavex class action lawsuit further alleges that on January 2, 2024, Anavex announced the Excellence study results and in doing so revealed that Anavex used the “MMRM” method – a statistical method not previously used by Anavex in its prior blarcamesine studies – to analyze the data and that the Excellence study failed to achieve statistical significance on all but one measure. On this news, the price of Anavex stock fell more than 35%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Anavex stock during the Class Period to seek appointment as lead plaintiff in the Anavex class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Anavex class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.
Levi & Korsinsky Notifies Shareholders of Anavex Life Sciences Corporation(AVXL) of a Class Action Lawsuit and an Upcoming Deadline
https://markets.businessinsider.com/news/stocks/levi-korsinsky-notifies-shareholders-of-anavex-life-sciences-corporation-avxl-of-a-class-action-lawsuit-and-an-upcoming-deadline-1033161577?op=1
THE LAWSUIT: A class action securities lawsuit was filed against Anavex Life Sciences Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
CASE DETAILS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company's claim noting "there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers'." Additionally, a biotech journalist commented on AVXL's findings stating "[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced "positive" outcomes from studies of its drug called blarcamesine - except the results were derived from efficacy endpoints that were not part of the original study designs." Following this news, AVXL's stock price fell by $2.47 per share, or approximately 20% to close at $9.58. Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that "the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results." Following this news, AVXL's stock price fell by $3.26 per share, or approximately 35%.
ACCORDING TO THE WGT PUMPERS, TGA PROVISIONAL HAS BEEN IMMINENT SINCE 2018 WITH A 100% CHANCE OF APPROVAL VERY SOON!!!!!!
What is going on in Austrailia?
EXPECT BAS2020 (FORMERLY KNOWN AS BASPARKS)TO CHANGE HIS USERNAME ONCE AGAIN NEXT WEEK!!!!!!!
EXPECT AVXL TO ANNOUNCE A2-73 TGA PROVISIONAL APPROVAL THE WGT PUMPERS CLAIMED WAS IMMINENT IN 2018, 2019, 2020, 2021, 2022, AND 2023 THIS WEEK!!!!!!!!!
DOES YOUR LOGIC ALSO APPLY TO THOSE NOT IN THE PLACEBO GROUP????????
The negative crap going on related to COVID would have amplified the placebo effect, because psychologically folks would be looking for positive events to help them deal with the negative.
THIS RUN-UP IS REAL UNLIKE ALL THE REST THAT CRASHED!!!!!!!!
YOU KNOW LIKE THE ANAVEX A2-73 TGA SAS CAT B APPROVAL IN 2020, WHICH THE WGT CREW CLAIMED WOULD GENERATE BILLIONS IN REVENUE!!!!!!!
GOOD LUCK AND GOD BLESS!!!!!!!
HOOOOOOOOOOLD LOOOOOOOOOOOOOOOONGS!!!!!!!!
THIS RUN-UP IS FOR REAL!!!!!!!!!
TOTAL NINSENSE FROM AN ARSE!!!!!!!
GOOD LUCK GOD BLESS!!!!!!!
MY FRIENDS TATTOO AND MR. ROURKE FROM FANTASY ISLAND ARE PLANNING ON BUYING AVXL SHARES!!!!!!!!!
HOLD LOOOOOOOOOOOOOOOONGS!!!!!!!
PURE NINSENSE!!!!!!!!🤣🤣🤣🤣🤣
Dr. Jiong Ma, PhD was named as Chairperson of the Boatd of Directors for Anavex Life Sciences approximately 6 months ago.
100% HOOOOOOOOOOOOOOOORSEPUCKY!!!!!!!!!
Recover? Where are you getting that? I've never seen a claim of recovery from anyone. Is this an attempt to create a straw man to shred?
WALNUTS AND A2-73!!!!!!!!!
$6.49 JUST PRINTED!!!!!!!
100% HORSEPUCKY!!!!
That is an 11 year old post. Who cares.
HOLD LOOOOOOOOONGS!!!!!!! MY FRIENDS ARE WILLING TO BUY 10000000000000 CENTILLION SHARES OF AVXL AT $1249 BEFORE WORLD WIDE APPROVAL IS ANNOUNCED NEXT WEEK!!!!!!
THAT IS A HUUUUUUUUUUUUUUUUUGE!!!!!!!!!!!
EXPECT BAS2020 (FORMERLY KNOWN AS BASPARKS) TO CLAIM THE CABAL HAS PREVENTED MISSLING FROM FILING AN NDA SINCE 2015 WITHIN THE NEXT 24 HOURS!!!!!
SO YOU ADMIT GEORGEJJL IS A LIAR, THANKS!!!!!!
So he sold his shares and rebought one time
YET, YOU ROUTINELY POST 7+ YEAR OLD VIDEOS AS PROOF A2-73 IS A MIRACLE CURE AND WORLDWIDE APPROVAL IS IMMINENT?????????
You are a hypocrite. You talk about post ancient posts. Then you post this post from over 7 years ago. That post has exceeded the statute of limitations.
HOW DO DOC'S PREDICTIONS COMPARE AGAINST THE AVXL WGT PUMPERS HERE ????
Somehow Doc can quantify the AA odds at one percent, but his track record on these types of predictions is pretty dismal. He always goes too low.
100% FUD!!!!!!!!!
PURE FUD!!!!!!!!!
100% B.S.!!!!!!!!
The editor of the Journal of Alzheimer's Disease is friend of Anavex George Perry.